GlassScriptPhysician profile
Brad Snodgrass
NPI 1134168842
$294.53
in general payments reported to CMS, 2019-2025
10 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.57 · 2024: $155 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.74 | 2024 | |
| Amgen INC. | $49.84 | 2024-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $49.81 | 2021-2025 | Arexvy, Shingrix, Bexsero |
| Corcept Therapeutics | $28.81 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $23.36 | 2024 | Gemtesa |
| Eisai INC. | $21.77 | 2024 | |
| Novo Nordisk INC | $14.95 | 2024 | Wegovy |
| Paratek Pharmaceuticals, INC. | $14.78 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $14.40 | 2024 | Capvaxive |
| Esperion Therapeutics, INC. | $14.07 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Snodgrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.